China Planning To Ban Gene Editing Technology Exports
Hindrance To Growing Sector?
Executive Summary
Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.
You may also be interested in...
Chinese Language Podcast: 集采, ADC交易, 基因编辑出口和中国生物制药内在矛盾
Recent major ADC deals, volume-based procurement (Jicai), China’s plan to ban gene-editing technology exports and the biotech paradox in China are the main topics for this new China Biotech Hot Topic podcast. Brian Yang and Dexter Yan discuss key aspects to watch and the implications for major players as well as the wider pharma sector.
China's Gene-Editing Baby Scientist Stirs Up Rare Disease Controversy
Jiankui He, the researcher behind China's world-shocking gene-edited babies scandal, now leaps into rare diseases research area but ethics oversight remain murky.
Chinese Biopharma Tycoons Down But Not Out In Latest Global Billionaire Ranking
China continues to dominate the latest list of global billionaires and top execs from domestic pharma firms Hengrui and Hansoh ranked among the wealthiest overall in the country, along with the founder of vaccine maker Zhifei Bio. A number of top Chinese biopharma business executives also featured in the global top 100 billionaires list.